Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and rare diseases. Its pipeline has included programs in areas such as ion-channel modulation, muscle and neuromuscular conditions, and other central-nervous-system indications. The company focuses on advancing drug candidates through clinical development rather than selling a broad commercial portfolio of established medicines. Its audience is specialists, trial sites and patients in selected high-need neurology and rare-disease segments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -221.7 | — |
| Q2 2025 | 0 | — | -198.2 | — |
| Q3 2025 | 0 | — | -173.4 | — |
| Q4 2025 | 0 | — | -145.6 | — |
| Q1 2026 | 0 | — | -130.5 | — |
| Q2 2026 | 0 | — | -137.3 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Wolverine World Wide, Inc. (WWW), Sixth Street Specialty Lending, Inc. (TSLX), Nordic American Tankers Limited (NAT), Live Oak Bancshares, Inc. (LOB), Securitize Corp. (SECZ), Stewart Information Services Corporation (STC)